文献速递前列腺癌

基于PSMA PET的PPP2前列腺癌风险分组更新:国际多中心注册研究

Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study.
PubMed 文献 · Eur Urol · 2025-05-02

本研究基于2013–2022年欧洲、美国及澳大利亚20家医院的6128例前列腺癌患者,按2:1分为开发队列(4044例)和验证队列(2084例),开发了整合PSMA PET参数的PPP2列线图。验证队列中,视觉和定量PPP2的C指数均为0.80,均优于NCCN风险评分(AUC 0.84 vs 0.76,p<0.001)。PPP2能准确预测3年和5年总生存概率,并已开发免费软件工具。

要点

  • PPP2列线图整合远处转移、PSMA表达评分及病灶总数或总肿瘤体积,预测总生存。
  • 验证队列中PPP2的C指数为0.80,优于NCCN风险评分的AUC 0.76。
  • 已开发免费软件工具(promise-pet.org)用于PROMISE和PPP2评估。

核心结论

  • PPP2列线图在国际多中心研究中得到改进,能准确预测前列腺癌3年和5年总生存概率。
  • PPP2的预测准确性优于NCCN风险评分。

研究设计与样本

  • 国际多中心注册研究,纳入2013–2022年间在欧洲、美国、澳大利亚20家医院接受PSMA-PET的6128例前列腺癌患者。
  • 研究者站点按2:1分为开发队列(4044例)和验证队列(2084例)。
  • 基于Cox回归模型及LASSO惩罚在开发队列中构建PPP2列线图,在验证队列中用Harrell C指数、校准图及ROC曲线与NCCN风险评分头对头比较。

主要发现

  • 预测因子包括远处转移(M1a、M1b、M1c)、PSMA表达评分以及病灶总数(视觉PPP2)或总肿瘤体积(定量PPP2)。
  • 验证队列C指数(95%CI)分别为视觉PPP2 0.80(0.78–0.82)和定量PPP2 0.80(0.79–0.82)。
  • 与NCCN风险评分比较(n=1034),PPP2的AUC为0.84 vs 0.76(p<0.001)。

关键数值与推荐

  • PPP2视觉版验证队列C指数0.80(95%CI 0.78–0.82)。
  • PPP2定量版验证队列C指数0.80(95%CI 0.79–0.82)。
  • 与NCCN风险评分比较(n=1034),AUC 0.84 vs 0.76,p<0.001。

临床怎么用

  • 可将PPP2列线图用于接受PSMA-PET的前列腺癌患者,预测3年和5年总生存概率。
  • PPP2评估准确性优于NCCN风险评分,可辅助风险分层。
  • 可使用免费软件工具(promise-pet.org)进行PROMISE和PPP2评估。

局限性

  • 研究为回顾性设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: We established prognostic nomograms incorporating prostate-specific membrane antigen (PSMA) positron emission tomography (PET) parameters standardised by Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE; PPP1). Here, we develop an updated PPP2 risk score from a large international multicentre registry study. METHODS: We included 6128 prostate cancer patients who underwent PSMA-PET at 20 hospitals in Europe, USA, and Australia between 2013 and 2022. Investigator sites were split 2:1 into the development (4044 patients) and validation (2084 patients) cohorts. We created nomograms of version 2 (PPP2) based on Cox regression models with the least absolute shrinkage and selection operator penalty for overall survival (development cohort). Performance of both nomograms was measured using Harrell's C-index and calibration plots and a head-to-head comparison with the National Comprehensive Cancer Network (NCCN) risk score by receiver operating characteristic curves (validation cohort). KEY FINDINGS AND LIMITATIONS: Predictors were distant metastases (extrapelvic nodal metastases [M1a], bone metastases [M1b], and visceral metastases [M1c]), PSMA expression score, and total lesion count (visual PPP2) or total tumour volume (quantitative PPP2). C-indices (95% confidence interval) in the validation cohort were 0.80 (0.78-0.82; visual) and 0.80 (0.79-0.82; quantitative), respectively. Accuracy of both the PPP2 nomograms was superior to the NCCN risk score (n = 1034, area under the curve 0.84 vs 0.76; p < 0.001). The retrospective design represents a limitation of the study. CONCLUSIONS AND CLINICAL IMPLICATIONS: PPP nomograms were improved in an international multicentre study to predict accurately the 3- and 5-yr overall survival probabilities of prostate cancer. PPP2 yielded superior accuracy to the NCCN risk score. A free software tool has been created for PROMISE and PPP2 assessments (promise-pet.org).

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Karpinski MJ, Rahbar K, Bögemann M, et al. Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study. Eur Urol. 2025. PMID: 40318933. doi:10.1016/j.eururo.2025.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。